CY1124191T1 - Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενεις - Google Patents
Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενειςInfo
- Publication number
- CY1124191T1 CY1124191T1 CY20211100473T CY211100473T CY1124191T1 CY 1124191 T1 CY1124191 T1 CY 1124191T1 CY 20211100473 T CY20211100473 T CY 20211100473T CY 211100473 T CY211100473 T CY 211100473T CY 1124191 T1 CY1124191 T1 CY 1124191T1
- Authority
- CY
- Cyprus
- Prior art keywords
- host disease
- versary
- grafv
- treatment
- transplant patients
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 208000024340 acute graft versus host disease Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01B—SOIL WORKING IN AGRICULTURE OR FORESTRY; PARTS, DETAILS, OR ACCESSORIES OF AGRICULTURAL MACHINES OR IMPLEMENTS, IN GENERAL
- A01B1/00—Hand tools
- A01B1/02—Spades; Shovels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Environmental Sciences (AREA)
- Mechanical Engineering (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Soil Sciences (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766830P | 2013-02-20 | 2013-02-20 | |
| PCT/IB2014/059067 WO2014128611A1 (en) | 2013-02-20 | 2014-02-18 | Treatment of graft versus host disease in transplant patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124191T1 true CY1124191T1 (el) | 2022-05-27 |
Family
ID=50236228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100473T CY1124191T1 (el) | 2013-02-20 | 2021-06-01 | Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενεις |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20160000811A1 (enExample) |
| EP (1) | EP2958624B1 (enExample) |
| JP (2) | JP6441822B2 (enExample) |
| KR (1) | KR102165514B1 (enExample) |
| CN (1) | CN105007981B (enExample) |
| AU (1) | AU2014220377B2 (enExample) |
| BR (1) | BR112015019197A2 (enExample) |
| CA (1) | CA2898565C (enExample) |
| CY (1) | CY1124191T1 (enExample) |
| DK (1) | DK2958624T3 (enExample) |
| EA (1) | EA030783B1 (enExample) |
| ES (1) | ES2873181T3 (enExample) |
| HR (1) | HRP20210891T1 (enExample) |
| HU (1) | HUE054330T2 (enExample) |
| LT (1) | LT2958624T (enExample) |
| MX (1) | MX369631B (enExample) |
| PL (1) | PL2958624T3 (enExample) |
| PT (1) | PT2958624T (enExample) |
| RS (1) | RS61933B1 (enExample) |
| SI (1) | SI2958624T1 (enExample) |
| SM (1) | SMT202100334T1 (enExample) |
| TW (1) | TWI648050B (enExample) |
| WO (1) | WO2014128611A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018017134A2 (pt) * | 2016-03-08 | 2019-01-15 | Kyorin Seiyaku Kk | tratamento de pacientes com transplante de célula-tronco hematopoiética |
| EP3831370A4 (en) * | 2018-07-27 | 2022-04-27 | Priothera Limited | AGENT FOR INHIBITING THE RECURRENCE OF HEMATOLOGICAL MALIGNITY IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION |
| CN117177748A (zh) * | 2020-11-04 | 2023-12-05 | 浩康生物系统公司 | 用于异基因造血干细胞移植的方法 |
| AU2021424131A1 (en) | 2021-01-28 | 2023-07-27 | Priothera Limited | Methods of treatment with s1p receptor modulators |
| EP4438037A1 (en) | 2021-01-28 | 2024-10-02 | Priothera SAS | Methods of treatment with s1p receptor modulators |
| JP2025506506A (ja) | 2022-02-16 | 2025-03-11 | プリオセラ エスエーエス | Ｓ１ｐ受容体モジュレーターと組み合わせたｃａｒ細胞を用いた処置方法 |
| EP4282407A1 (en) | 2022-05-27 | 2023-11-29 | Priothera SAS | Treatment of cancer with s1p receptor agonists |
| WO2025109119A1 (en) | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1011694A4 (en) * | 1996-11-15 | 2000-11-15 | Baxter Int | TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION |
| US6383481B1 (en) | 1998-03-30 | 2002-05-07 | Japan Immunoresearch Laboratories Co., Ltd. | Method for transplantation of hemopoietic stem cells |
| JPH11343242A (ja) * | 1998-03-30 | 1999-12-14 | Otsuka Pharmaceut Co Ltd | 造血幹細胞移植用剤 |
| AU2002332289B2 (en) * | 2001-09-27 | 2007-05-10 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
| US7482491B2 (en) * | 2002-09-19 | 2009-01-27 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative, addition salt thereof, and immunosuppressant |
| AU2005264431B2 (en) * | 2004-07-16 | 2010-08-19 | Kyorin Pharmaceutical Co., Ltd. | Method of effectively using medicine and method concerning prevention of side effect |
| JP4966019B2 (ja) * | 2005-01-06 | 2012-07-04 | キッセイ薬品工業株式会社 | 慢性移植片対宿主症におけるドライアイの予防および治療剤 |
| WO2011140170A1 (en) | 2010-05-04 | 2011-11-10 | Yeda Research And Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
| AU2011249789B2 (en) | 2010-05-06 | 2015-03-19 | Novartis Ag | Dosage regimen of diaryl sulfide derivatives |
-
2014
- 2014-02-18 LT LTEP14708330.7T patent/LT2958624T/lt unknown
- 2014-02-18 HR HRP20210891TT patent/HRP20210891T1/hr unknown
- 2014-02-18 PL PL14708330T patent/PL2958624T3/pl unknown
- 2014-02-18 US US14/768,744 patent/US20160000811A1/en not_active Abandoned
- 2014-02-18 BR BR112015019197A patent/BR112015019197A2/pt not_active Application Discontinuation
- 2014-02-18 PT PT147083307T patent/PT2958624T/pt unknown
- 2014-02-18 CN CN201480009413.4A patent/CN105007981B/zh active Active
- 2014-02-18 HU HUE14708330A patent/HUE054330T2/hu unknown
- 2014-02-18 AU AU2014220377A patent/AU2014220377B2/en active Active
- 2014-02-18 MX MX2015010833A patent/MX369631B/es active IP Right Grant
- 2014-02-18 WO PCT/IB2014/059067 patent/WO2014128611A1/en not_active Ceased
- 2014-02-18 RS RS20210626A patent/RS61933B1/sr unknown
- 2014-02-18 SM SM20210334T patent/SMT202100334T1/it unknown
- 2014-02-18 JP JP2015558580A patent/JP6441822B2/ja active Active
- 2014-02-18 ES ES14708330T patent/ES2873181T3/es active Active
- 2014-02-18 DK DK14708330.7T patent/DK2958624T3/da active
- 2014-02-18 KR KR1020157022190A patent/KR102165514B1/ko active Active
- 2014-02-18 SI SI201431824T patent/SI2958624T1/sl unknown
- 2014-02-18 CA CA2898565A patent/CA2898565C/en active Active
- 2014-02-18 EA EA201591522A patent/EA030783B1/ru not_active IP Right Cessation
- 2014-02-18 EP EP14708330.7A patent/EP2958624B1/en active Active
- 2014-02-19 TW TW103105523A patent/TWI648050B/zh active
-
2018
- 2018-01-29 US US15/882,392 patent/US11224604B2/en active Active
- 2018-11-22 JP JP2018219258A patent/JP6633170B2/ja active Active
-
2021
- 2021-06-01 CY CY20211100473T patent/CY1124191T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124191T1 (el) | Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενεις | |
| IL270982A (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
| MX2014003832A (es) | Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo. | |
| EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
| EA201591501A1 (ru) | Терапевтические средства на основе csf-1 | |
| EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
| BR112014005355A2 (pt) | células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença | |
| BR112014031424A2 (pt) | tratamento de células pluripotentes | |
| IL239603A0 (en) | Treatment of vasculopathy with prostacyclin and mesenchymal stem cells | |
| EA201600252A1 (ru) | Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования | |
| EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
| BR112015021869A2 (pt) | Domínios gla como agentes alvo | |
| UY33956A (es) | Anticuerpo del factor antitisular humano y sus usos para tratar cáncer | |
| MX2016005824A (es) | Metodo de cultivo celular. | |
| EP3634584A4 (en) | USE OF CD39 AND CD103 FOR THE IDENTIFICATION OF REACTIVE HUMAN TUMOR CELLS FOR THE TREATMENT OF CANCER | |
| CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
| MX2016013910A (es) | Tratamiento del cancer. | |
| MX378857B (es) | Celulas huespedes modificadas y usos de las mismas. | |
| CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma | |
| EA201591796A1 (ru) | Антитела к cd52 | |
| MX2016006656A (es) | Metodos para tratar rechazo mediado por anticuerpos en pacientes de trasplante de organos con inhibidor de c1-esterasa. | |
| MX2015008436A (es) | Composiciones para permeabilizar celulas sanguineos fijos y sus usos. | |
| BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| MX2021010546A (es) | Composiciones y metodos para tratamiento de la piel. | |
| TR201811308T4 (tr) | Kanser kok hücrelerini azaltan anti-emp2 tedavisi. |